Erratum: A new trend in personalized medicine: Rapid detection of SNPs in drug transporter genes by the smartamp method (Clinical Pharmacology and Therapeutics (2011) 89 (617-620) DOI:10.1038/clpt.2011.13);A new trend in personalized medicine: Rapid detection of SNPs in drug transporter genes by the Smartamp method

Clinical Pharmacology and Therapeutics

Volumn 89, Issue 4, 2011, Pages 617-620

  Aw, W ^a   Lezhava, A ^a   Hyashizaki, Y ^a   Ishikawa, T ^a  

^a RIKEN YOKOHAMA INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; AZATHIOPRINE; CAMPTOTHECIN; CARRIER PROTEIN; DNA POLYMERASE; DRUG TRANSPORTER; GANCICLOVIR; LAMIVUDINE; MERCAPTOPURINE; METHOTREXATE; MULTIDRUG RESISTANCE PROTEIN 4; TENOFOVIR; THIOPURINE METHYLTRANSFERASE; TIOGUANINE; UNCLASSIFIED DRUG; ZIDOVUDINE;

ARTICLE; BLOOD TOXICITY; COST EFFECTIVENESS ANALYSIS; DNA ISOLATION; DRUG METABOLISM; DRUG TRANSPORT; ENTERITIS; GENE AMPLIFICATION; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REAL TIME POLYMERASE CHAIN REACTION; RECOMMENDED DRUG DOSE; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 79952991972     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.57     Document Type: Erratum

References (32)

1. Mitani, Y. et al. Rapid SNp diagnostics using asymmetric isothermal amplification and a new mismatch-suppression technology. Nat. Methods 4, 257-262 (2007). (Pubitemid 46358877)
2. Lezhava, A. et al. Exciton primer-mediated SNp detection in Smartamp2 reactions. Hum. Mutat. 31, 208-217 (2010).
3. Mitani, Y. et al. Rapid and cost-effective SNp detection method: application of Smartamp2 to pharmacogenomics research. Pharmacogenomics 10, 1187-1197 (2009).
4. Frueh, F.W. et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 28, 992-998 (2008).
5. Lesko, L.J. The critical path of warfarin dosing: finding an optimal dosing strategy using pharmacogenetics. Clin. Pharmacol. Ther. 84, 301-303 (2008).
6. Cusatis, G. & Sparreboom, A. Pharmacogenomic importance of aBCG2. Pharmacogenomics 9, 1005-1009 (2008).
7. Ishikawa, T. et al. The genetic polymorphism of drug transporters: functional analysis approaches. Pharmacogenomics 5, 67-99 (2004). (Pubitemid 38088481)
8. Weinshilboum, R.M. & Sladek, S.L. Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am. J. Hum. Genet. 32, 651-662 (1980). (Pubitemid 10061685)
9. Anstey, A., Lennard, L., Mayou, S.C. & Kirby, J.D. Pancytopenia related to azathioprine-an enzyme deficiency caused by a common genetic polymorphism: a review. J. R. Soc. Med. 85, 752-756 (1992).
10. Stolk, J.N. et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 41, 1858-1866 (1998). (Pubitemid 28465541)
11. Yates, C.R. et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann. Intern. Med. 126, 608-614 (1997). (Pubitemid 27172187)
12. Black, A.J. et al. Thiopurine methyltransferase genotype predicts therapylimiting severe toxicity from azathioprine. Ann. Intern. Med. 129, 716-718 (1998). (Pubitemid 28507145)
13. Clunie, G.P. & Lennard, L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford). 43, 13-18 (2004). (Pubitemid 38088361)
14. Takatsu, N. et al. Adverse reactions to azathioprine cannot be predicted by thiopurine S-methyltransferase genotype in Japanese patients with inflammatory bowel disease. J. Gastroenterol. Hepatol. 24, 1258-1264 (2009).
15. Krishnamurthy, P. et al. Transporter-mediated protection against thiopurineinduced hematopoietic toxicity. Cancer Res. 68, 4983-4989 (2008).
16. Schuetz, J.D. et al. MRp4: a previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat. Med. 5, 1048-1051 (1999). (Pubitemid 29439577)
17. Adachi, M. et al. Expression of MRp4 confers resistance to ganciclovir and compromises bystander cell killing. J. Biol. Chem. 277, 38998-39004 (2002). (Pubitemid 35154766)
18. Anderson, P.L., Lamba, J., Aquilante, C.L., Schuetz, E. & Fletcher, C.V. Pharmacogenetic characteristics of indinavir, Zidovudine, And lamivudine therapy in HiV-infected adults: a pilot study. J. Acquir. Immune Defic. Syndr. 42, 441-449 (2006). (Pubitemid 44050891)
19. Imaoka, T., Kusuhara, H., Adachi, M., Schuetz, J.D., Takeuchi, K. & Sugiyama, Y. Functional involvement of multidrug resistance-associated protein 4 (MRp4/ aBCC4) in the renal elimination of the antiviral drugs adefovir and tenofovir. Mol. Pharmacol. 71, 619-627 (2007). (Pubitemid 46147926)
20. Lee, K., Klein-Szanto, A.J. & Kruh, G.D. Analysis of the MRp4 drug resistance profile in transfected NiH3T3 cells. J. Natl. Cancer Inst. 92, 1934-1940 (2000). (Pubitemid 32036924)
21. Chen, Z.S. et al. Analysis of methotrexate and folate transport by multidrug resistance protein 4 (aBCC4): MRp4 is a component of the methotrexate efflux system. Cancer Res. 62, 3144-3150 (2002).
22. Wielinga, P.R. et al. Thiopurine metabolism and identification of the thiopurine metabolites transported by MRp4 and MRp5 overexpressed in human embryonic kidney cells. Mol. Pharmacol. 62, 1321-1331 (2002). (Pubitemid 35407456)
23. Tian, Q. et al. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res. 22, 1837-1853 (2005). (Pubitemid 41504337)
24. Ando, M., Ando, Y., Hasegawa, Y., Sekido, Y., Shimokata, K. & Horibe, K. Genetic polymorphisms of thiopurine S-methyltransferase and 6-mercaptopurine toxicity in Japanese children with acute lymphoblastic leukaemia. Pharmacogenetics 11, 269-273 (2001). (Pubitemid 32319877)
25. Ban, H. et al. The multidrug-resistance protein 4 polymorphism is a new factor accounting for thiopurine sensitivity in Japanese patients with inflammatory bowel disease. J. Gastroenterol. 45, 1014-1021 (2010).
26. Lichtenstein, G.R., Sbreu, M.T., Cohen, R. & Tremaine, W. [american Gastroenterological association institute technical review on corticosteroids, Immunomodulators, And infliximab in inflammatory bowel disease]. Rev. Gastroenterol. Mex. 71, 351-401 (2006).
27. Hibi, T., Naganuma, M., Kitahora, T., Kinjyo, F. & Shimoyama, T. Low-dose azathioprine is effective and safe for maintenance of remission in patients with ulcerative colitis. J. Gastroenterol. 38, 740-746 (2003). (Pubitemid 37161337)
28. Ishikawa, T., Sakurai, A., Hirano, H., Lezhava, A., Sakurai, M. & Hayashizaki, Y. Emerging new technologies in pharmacogenomics: rapid SNp detection, Molecular dynamic simulation, And QSaR analysis methods to validate clinically important genetic variants of human aBC Transporter aBCB1 (p-gp/MDR1). Pharmacol. Ther. 126, 69-81 (2010).
29. Aw, W. et al. Pharmacogenomics of humans aBC transporters: detection of clinically important SNps by Smartamp2 method. Curr. Pharm. Biotechnol. (2011); e-pub ahead of print 30 November 2010.
30. Ota, I. et al. Association between breast cancer risk and the wild-type allele of human aBC transporter aBCC11. Anticancer Res. 30, 5189-5194 (2010).
31. Aomori, T. et al. Rapid single-nucleotide polymorphism detection of cytochrome p450 (CYp2C9) and vitamin K epoxide reductase (VKORC1) genes for the warfarin dose adjustment by the SMart-amplification process version . Clin. Chem. 55, 804-812 (2009).
32. Watanabe, J. et al. Use of a competitive probe in assay design for genotyping of the UGT1a1 *28 microsatellite polymorphism by the smart amplification process. BioTechniques 43, 479-484 (2007). (Pubitemid 350041543)